ERBB2 and breast cancer: The concomitant lack of ER, PR, and HER2 defines Triple- Negative Breast Cancer (TNBC), a subtype that comprises 15-20% of all BC, highly prevalent in women younger than 40, Black, or with BRCA1 gene mutation, and represents the most challenging BC to be treated.